Literature DB >> 15475320

Pharmaceutical approaches to the treatment of obesity.

Ronald J Jandacek1, Stephen C Woods.   

Abstract

The recent increase in pharmaceutical companies' efforts toward the treatment of obesity reflects recognition of the related health risks, the growth of knowledge about mechanisms that control energy balance, and the potential market for new compounds. The current patent literature gives a picture of the targets that are available for pharmaceutical intervention; these include signals of satiety and signals related to fat storage that act in the hypothalamus. The regulation of energy use and storage in adipocytes and the reduction of intestinal absorption of energy are also pharmaceutical focus areas. The multiplicity of targets illustrates not only the many potential approaches to the treatment of obesity but also the complexity and redundancy of the processes that regulate energy storage in the body.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15475320     DOI: 10.1016/S1359-6446(04)03244-1

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  8 in total

1.  The 'Tyranny of choices' in the ingestion-controlling network.

Authors:  Michael Myslobodsky
Journal:  Obes Facts       Date:  2009-12-04       Impact factor: 3.942

2.  Inhibitory effects of corni fructus extract on angiogenesis and adipogenesis.

Authors:  Jae-Ho Hwang; Jong-Deog Kim
Journal:  Korean J Physiol Pharmacol       Date:  2011-02-28       Impact factor: 2.016

3.  The role of ATF-2 family transcription factors in adipocyte differentiation: antiobesity effects of p38 inhibitors.

Authors:  Toshio Maekawa; Wanzhu Jin; Shunsuke Ishii
Journal:  Mol Cell Biol       Date:  2009-11-30       Impact factor: 4.272

4.  TLQP-21, a VGF-derived peptide, increases energy expenditure and prevents the early phase of diet-induced obesity.

Authors:  A Bartolomucci; G La Corte; R Possenti; V Locatelli; A E Rigamonti; A Torsello; E Bresciani; I Bulgarelli; R Rizzi; F Pavone; F R D'Amato; C Severini; G Mignogna; A Giorgi; M E Schininà; G Elia; C Brancia; G-L Ferri; R Conti; B Ciani; T Pascucci; G Dell'Omo; E E Muller; A Levi; A Moles
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-18       Impact factor: 11.205

5.  Biochemical and anthropometric effects of a weight loss dietary supplement in healthy men and women.

Authors:  Cameron G McCarthy; Robert E Canale; Rick J Alleman; Jacob P Reed; Richard J Bloomer
Journal:  Nutr Metab Insights       Date:  2011-12-06

6.  Targeted inactivation of GPR26 leads to hyperphagia and adiposity by activating AMPK in the hypothalamus.

Authors:  Daohong Chen; Xiaolei Liu; Weiping Zhang; Yuguang Shi
Journal:  PLoS One       Date:  2012-07-16       Impact factor: 3.240

7.  Pancreatic lipase inhibitory activity of taraxacum officinale in vitro and in vivo.

Authors:  Jian Zhang; Min-Jung Kang; Myung-Jin Kim; Mi-Eun Kim; Ji-Hyun Song; Young-Min Lee; Jung-In Kim
Journal:  Nutr Res Pract       Date:  2008-12-31       Impact factor: 1.926

8.  Sibutramine effects on central mechanisms regulating energy homeostasis.

Authors:  João R Araújo; Fátima Martel
Journal:  Curr Neuropharmacol       Date:  2012-03       Impact factor: 7.363

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.